Condition
Symptomatic Hypertrophic Cardiomyopathy (HCM)
Total Trials
1
Recruiting
0
Active
1
Completed
0
Key Insights
Highlights
Treatment Research
2 treatments under study, led by Aficamten
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 1 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
1Total
Phase 2/3 (1)
Trial Status
Enrolling By Invitation1
Clinical Trials (1)
Showing 1 of 1 trials
Showing all 1 trials
Research Network
Common Treatments
- Aficamten1
- Aficamten 5 20 Mg1
Active Sponsors
- Cytokinetics1
- Cytokinetics Inc.1
Top Investigators
Cytokinetics